> Detailanzeige

Damaj, Gandhi; Gressin, Rémy; Bouabdallah, Krimo; Cartron, Guillaume; Choufi, Bachra; Gyan, Emmanuel; Banos, Anne; Jaccard, Arnaud; Park, Sophie; Tournilhac, Olivier; Schiano-de Collela, Jean-Marc; Voillat, Laurent; Joly, Bertrand; Le Gouill, Steven; Saad, Alain; Cony-Makhoul, Pascale; Vilque, Jean-Pierre; Sanhes, Laurence; Schmidt-Tanguy, Aline; Bubenheim, Michael; Houot, Roch; Diouf, Momar; Marolleau, Jean-Pierre; Béné, Marie-Christine; [...]

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
  • Beteiligte: Damaj, Gandhi; Gressin, Rémy; Bouabdallah, Krimo; Cartron, Guillaume; Choufi, Bachra; Gyan, Emmanuel; Banos, Anne; Jaccard, Arnaud; Park, Sophie; Tournilhac, Olivier; Schiano-de Collela, Jean-Marc; Voillat, Laurent; Joly, Bertrand; Le Gouill, Steven; Saad, Alain; Cony-Makhoul, Pascale; Vilque, Jean-Pierre; Sanhes, Laurence; Schmidt-Tanguy, Aline; Bubenheim, Michael; Houot, Roch; Diouf, Momar; Marolleau, Jean-Pierre; Béné, Marie-Christine; [...]
  • Erschienen: American Society of Clinical Oncology (ASCO), 2013
  • Erschienen in: Journal of Clinical Oncology, 31 (2013) 1, Seite 104-110
  • Sprache: Englisch
  • DOI: 10.1200/jco.2012.43.7285
  • ISSN: 0732-183X; 1527-7755
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Purpose To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas. Patients and Methods Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma who progressed after one or more lines of prior chemotherapy received bendamustine at 120 mg/m2 per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Of the 60 patients included, 27 (45%) were refractory to their last prior chemotherapy, and the median duration of the best previous response was 6.6 months. Histology was predominantly angioimmunoblastic lymphadenopathy and PTCL not otherwise specified. The disease was disseminated in the majority of patients (87%). The median number of previous lines of chemotherapy was one (range, one to three). Twenty patients (33%) received fewer than three cycles of bendamustine, mostly because of disease progression. In the intent-to-treat population, the ORR was 50%, including complete response in 17 patients (28%) and partial response in 13 patients (22%). Bendamustine showed consistent efficacy independent of major disease characteristics. The median values for DoR, PFS, and OS were 3.5, 3.6, and 6.2 months, respectively. The most frequent grade 3 to 4 adverse events were neutropenia (30%), thrombocytopenia (24%), and infections (20%). Conclusion Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.
  • Zugangsstatus: Freier Zugang